Want to see ACXP full AI Analyst Report?
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-31.51% Downside)
Action:Reiterated
Date:10/17/26
ACXP scores low primarily due to weak financial performance (pre-revenue, ongoing losses, and highly concerning/volatile cash outflows) and bearish technicals (below key moving averages with negative MACD). The earnings call adds some support via regulatory and clinical progress and a higher cash balance, but near-term funding needs and dilution risk remain significant, limiting the overall score.
Positive Factors
Regulatory pathway progress
FDA engagement creates a clearer potential registration pathway for ibezapolstat than the company had previously disclosed. Acceptance of PATHFINDER as supportive evidence could improve development efficiency, although eventual progress still depends on robust, consistent clinical results.
Negative Factors
Pre-revenue operating model
The absence of product revenue means Acurx cannot currently fund operations through customers or commercial sales. Persistent losses also leave future value dependent on clinical progress, regulatory approval, and eventual commercialization or partnering success rather than an established earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory pathway progress
FDA engagement creates a clearer potential registration pathway for ibezapolstat than the company had previously disclosed. Acceptance of PATHFINDER as supportive evidence could improve development efficiency, although eventual progress still depends on robust, consistent clinical results.
Read all positive factors
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.31M
Dividend YieldN/A
Average Volume (3M)86.46K
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue GrowthN/A
EPS Growth71.66%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.55
Shares Outstanding5,559,405
10 Day Avg. Volume72,309
30 Day Avg. Volume86,463
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-0.55
Enterprise Value/Market Cap-0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$17.00Price Target Upside1064.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Acurx Pharmaceuticals Business Overview & Revenue Model
Company Description
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a n...
How the Company Makes Money
As a clinical-stage company, Acurx does not have a broadly established, recurring product-revenue base from marketed drugs; its business model is centered on advancing drug candidates through clinical development with the goal of eventual commerci...
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful regulatory, scientific and IP progress (FDA engagement on a potential single pivotal Phase III pathway, trademark allowance for Syfbezi, fully funded PATHFINDER, manufacturing readiness, partnerships, and strengthened cash vs year-end) while also highlighting material challenges: the need to secure substantial funding to run a large international Phase III (ASPIRE), a limited stated runway (~1 year), rising R&D costs tied to trial startup, ongoing operating losses, and potential dilution from financings. On balance the call emphasized significant program and regulatory momentum but also clear near-term financing and execution risks.Positive Updates
Regulatory Progress — FDA Dialogue and Branding
Positive outcome from July FDA meeting: FDA is open to considering a single Phase III (ASPIRE) as pivotal when evaluated with totality of evidence (including PATHFINDER) at a pre-NDA meeting. Company received FDA conditional acceptance and USPTO trademark allowance for the proprietary name Syfbezi (ibezapolstat). Maintains QIDP and Fast Track designations for CDI and SME status in the EU.
Negative Updates
ASPIRE Phase III Funding Uncertainty
Advancement to the international ASPIRE Phase III pivotal trial is contingent on securing public/private funding or partnerships; funding efforts are ongoing and not yet secured.
Read all updates
Q2-2026 Updates
Positive
Negative
Regulatory Progress — FDA Dialogue and Branding
Positive outcome from July FDA meeting: FDA is open to considering a single Phase III (ASPIRE) as pivotal when evaluated with totality of evidence (including PATHFINDER) at a pre-NDA meeting. Company received FDA conditional acceptance and USPTO trademark allowance for the proprietary name Syfbezi (ibezapolstat). Maintains QIDP and Fast Track designations for CDI and SME status in the EU.
Read all positive updates
Company Guidance
On the call Acurx provided detailed clinical and financial guidance: the PATHFINDER 20‑patient open‑label recurrent CDI trial is fully funded, start‑up is underway and enrollment is expected to begin in Q4 2026 (anticipated enrollment ~1–1.5 years), while the single international Phase III ASPIRE pivotal trial is planned but contingent on additional public/private funding; FDA indicated it will consider the totality of evidence (PATHFINDER + ASPIRE and other trials) at a pre‑NDA meeting, acknowledged an 8‑week post‑treatment assessment and accepted a non‑inferiority approach versus vancomycin with a typical 10% lower‑bound margin, and PATHFINDER data could enable LPAD filing for recurrent CDI; financially the company had $10.7M cash at June 30, 2026 (up from $7.6M at Dec 31, 2025), raised approximately $2.5M gross in the quarter via a Registered Direct Offering plus $0.8M from the Equity Line, had earlier arranged up to $7.1M via a registered direct of 825,085 shares at $3.03 and concurrent short‑term warrants for up to 1.65M shares at $2.78 (24‑month expiry), and noted cash/resources (including remaining Equity Line availability) to fund PATHFINDER and operations for at least one year; Q2 R&D was $1.1M vs $0.5M LY (+$0.6M), 6‑month R&D $1.4M vs $1.1M LY (+$0.3M); Q2 G&A $1.2M vs $1.7M LY (‑$0.5M), 6‑month G&A $2.6M vs $3.3M LY (‑$0.7M); net loss Q2 $2.3M or $0.53/diluted share (vs $2.2M or $1.89 LY) and 6‑month net loss $3.9M or $1.13/diluted share (vs $4.4M or $4.01 LY); shares outstanding were 4,683,253 as of June 30, 2026, and the company holds 6 U.S. and 10 international patents, received USPTO trademark allowance and FDA conditional acceptance for the brand name Syfbezi, and retains QIDP/Fast Track designations.Acurx Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.56M | -7.97M | 20.12K | -14.58M | -12.09M | -12.75M |
| Net Income | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
Balance Sheet | ||||||
| Total Assets | 10.98M | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Cash, Cash Equivalents and Short-Term Investments | 10.66M | 7.56M | 3.71M | 7.47M | 9.11M | 12.96M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.83M | 2.42M | 3.24M | 3.04M | 2.06M | 843.91K |
| Stockholders Equity | 8.15M | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
Cash Flow | ||||||
| Free Cash Flow | -6.18M | -6.79M | -10.38M | -9.80M | -7.54M | -5.01M |
| Operating Cash Flow | -6.18M | -6.79M | -10.38M | -9.80M | -7.54M | -5.01M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 10.78M | 10.64M | 6.62M | 8.16M | 3.70M | 14.80M |
Acurx Pharmaceuticals Technical Analysis
Negative
1.46
Price Trends
1.34
Negative
1.43
Negative
2.02
Negative
Market Momentum
-0.06
Positive
33.95
Neutral
32.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 1.46 is above the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.34, and below the 200-day MA of 2.02, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 33.95 is Neutral, neither overbought nor oversold. The STOCH value of 32.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.07M | -0.19 | -67.15% | ― | ― | 57.48% | |
45 Neutral | $6.31M | -0.32 | -124.74% | ― | ― | 71.66% | |
45 Neutral | $18.30M | -1.19 | -207.47% | ― | ― | 38.55% | |
42 Neutral | $7.94M | -0.29 | -181.02% | ― | ― | 66.94% | |
41 Neutral | $29.85M | -0.65 | -160.72% | ― | 893.01% | 41.74% | |
39 Underperform | $2.08M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
ACXP
Acurx Pharmaceuticals
1.14
-5.47
-82.80%
SNGX
Soligenix
0.37
-1.20
-76.60%
GOVX
GeoVax Labs
0.21
-14.11
-98.56%
COCP
Cocrystal Pharma
0.95
-0.28
-22.76%
CTXR
Citius Pharmaceuticals
0.40
-1.21
-75.05%
ALGS
Aligos Therapeutics
4.78
-4.99
-51.07%
Acurx Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Acurx Pharmaceuticals Shareholders Approve Governance and Auditing Changes
Positive
Oct 16, 2026
At the October 16, 2026 Annual Meeting of Stockholders of Acurx Pharmaceuticals, Inc., a quorum was achieved with approximately 52.83% of the 5,471,297 outstanding common shares represented in person or by proxy. Stockholders considered two corpor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.